NasdaqCM:IMUXBiotechs
A Look At Immunic (IMUX) Valuation After CEO Transition MS Data And US$200m Financing
Immunic (IMUX) has been in focus after a busy stretch, with board and leadership changes, fresh clinical data in multiple sclerosis, and a large private placement that brought in new and existing institutional investors.
See our latest analysis for Immunic.
The recent CEO transition plan, fresh MS data and the US$200.0m private placement appear to have coincided with sharp short term momentum, with a 7 day share price return of 47.18% and year to date share price return of 56.52%. This is set...